Working… Menu

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02234986
Recruitment Status : Completed
First Posted : September 9, 2014
Last Update Posted : September 6, 2018
Information provided by (Responsible Party):
CASI Pharmaceuticals, Inc.